Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and h...

Gilead Sciences Inc (GILD) has a valuation score of 74/100 (moderate), profitability score of 62/100 (moderate), financial health score of 73/100 (moderate), Piotroski F-Score of 8/9, Altman Z-Score of 4.17 (safe zone), revenue growth of +2.6% YoY.

Neutral

Analyst Consensus

Strong Buy

Wall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026

Analyst Recommendations37 analysts · 2026-08-01
9
21
7
Strong Buy 9Buy 21Hold 7Sell 0Strong Sell 0
Gilead Sciences Inc (GILD) Valuation & P/E History →Gilead Sciences Inc (GILD) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →